Home › Autoimmune Diseases › Massachusetts › Boston
Autoimmune Diseases clinical trials in Boston, MA
13 studies for Autoimmune Diseases are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
RecruitingPhase 3
- Tufts Medical Center, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Massachusetts General Hospital, Boston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Massachusetts General Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- and 1 more
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecruitingPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RecruitingPhase 3
- Boston Children's Cancer Center, Boston
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
RecruitingPhase 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecruitingPhase 1/2
- Brigham and Women's Hospital, Boston
Testimonials and Navigation in Rheumatology
Recruiting
- Brigham Women's Hospital, Boston
About Autoimmune Diseases
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
More about Autoimmune Diseases on MedlinePlus
Autoimmune Diseases trials in other cities
- Houston, TX21 studies
- Washington, DC19 studies
- New York City, NY19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Portland, OR8 studies
- Milwaukee, WI8 studies
- Atlanta, GA8 studies
- Cleveland, OH8 studies
Other studies in Boston
- Breast Cancer110 studies
- Non-Small Cell Lung Cancer89 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer60 studies
- Depression51 studies
- Endometrial Cancer50 studies
- Acute Myeloid Leukemia45 studies
- Pancreatic Cancer44 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.